Neoplasms

All Conditions

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Gland and Hormone Related Diseases

Symptoms and General Pathology

Rare Diseases

Carcinoma

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial

Disease Progression

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Endocrine Gland Neoplasms

Ovarian Diseases

Adnexal Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Genital Neoplasms, Female

Urogenital Neoplasms

Endocrine System Diseases

Gonadal Disorders

Ovarian Cancer

Ovarian Epithelial Cancer

Antineoplastic Agents

Antirheumatic Agents

Dermatologic Agents

Reproductive Control Agents

All Drugs and Chemicals

Anti-Inflammatory Agents

Analgesics

Micronutrients

Hematinics

Vitamins

Methotrexate

Angiogenesis Inhibitors

Celecoxib

Cyclophosphamide

Antimetabolites

Enzyme Inhibitors

Folic Acid

Vitamin B Complex

Folic Acid Antagonists

Immunosuppressive Agents

Immunologic Factors

Anti-Inflammatory Agents, Non-Steroidal

Analgesics, Non-Narcotic

Cyclooxygenase 2 Inhibitors

Cyclooxygenase Inhibitors

Antineoplastic Agents, Alkylating

Alkylating Agents

Folinic Acid

Folate

Vitamin B9

Maintenance Treatment for Ovary Carcinoma by Metronomic Chemotherapy

Metronomic Chemotherapy as maintenance treatment for patients with Ovarian Cancer

* Cytophosphan tab 50 mg -1x1 per day, continuous
* Celecoxib tab 200 mg - 1x2 per day, continuous
* Methotrexate tab 2.5 mg - 1x2 per day, 2 days weekly

Cytophosphan, Celecoxib, Methotrexate

David Loven, M.D.

Preclinical studies showed that metronomic chemotherapy can induce tumor regression secondary to apoptosis of the tumor blood vessels. This effect was increased by combining metronomic chemotherapy with anti-angiogenic drugs. Metronomic chemotherapy has already proved clinical effects too, especially on patients with breast or prostate carcinoma. This study is aimed to test the efficacy of an experimental metronomic chemotherapy regimen in a cohort of patients with ovarian cancer. Patients will receive the proposed regimen as maintenance treatment following response induction by the conventional maximal tolerated dose (MTD) regimen of Carboplatin and Paclitaxel. Our regimen will include Cytophosphan combined with two agents which are expected to act as indirect angiogenic inhibitors: (a) celecoxib, as a selective COX-2 inhibitor and (b) low-dose Methotrexate, as successfully practiced for suppressing the inflammatory manifestations of rheumatoid arthritis. All components of our regimen will be administered orally and continuously for one year based on the hypothesis that its anti-angiogenic properties will be able to suppress the recovery of residual disease, thus extending the time to progression (TTP), and possibly the overall survival as well.

Maintenance Treatment for Ovarian Carcinoma in Remission by an Antiangiogenic Treatment Strategy

Maintenance Treatment for Ovarian Carcinoma in Remission by an Antiangiogenic Treatment Strategy With Metronomic/Oral Chemotherapy (Cytophosphan Combined With Low-dose Methotrexate)and COX-2 Inhibition (Celecoxib)

Median time to progression of the cohort will be compared with equivalent measure in the literature.

HaEmek Medical Center, Israel

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Maintenance Treatment for Ovarian Carcinoma in Remission by an Antiangiogenic Treatment Strategy	NCT01175772	Ovarian Carcino...	Cytophosphan, C...	20 Years - 80 Years	HaEmek Medical Center, Israel
Maintenance Treatment for Ovarian Carcinoma in Remission by an Antiangiogenic Treatment Strategy	NCT01175772	Ovarian Carcino...	Cytophosphan, C...	20 Years - 80 Years	HaEmek Medical Center, Israel

Spots Global Cancer Trial Database for cytophosphan, celecoxib, methotrexate